Chemotherapy

Title Average Ratingsort descending
Gemcitabine 0.00%
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. 0.00%
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.... 0.00%
WITHDRAWN: Multi-agent chemotherapy for early breast cancer. 0.00%
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer........ 0.00%
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. 30.00%
Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced... 30.00%
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... 30.00%
Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment 30.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... 30.00%
A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillar... 30.00%
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the 30.00%
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic 40.00%
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non..... 40.00%
One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma 40.00%
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. 40.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... 40.00%
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. 40.00%
Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations. 40.00%
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. 40.00%
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco 40.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat 40.00%
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients .... 40.00%
Ependymoma. 40.00%
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. 50.00%
Case report of a pituitary macroadenoma treated with artemether. 50.00%
Chemoradiotherapy in malignant glioma: standard of care and future directions. 50.00%
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. 50.00%
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal 50.00%
Lessons learned in the development of targeted therapy for malignant gliomas 50.00%
WITHDRAWN: Ovarian ablation for early breast cancer. 50.00%
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? 50.00%
Real world treatment patterns of gastrointestinal stromal tumor patients. 50.00%
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer 50.00%
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. 50.00%
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. 50.00%
Tumoral angiogenesis: review of the literature. 50.00%
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and 50.00%
Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. 50.00%
MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in pati 50.00%
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas ... 50.00%
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. 50.00%
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer 50.00%
Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast........ 60.00%
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo 60.00%
Anti-angiogenic therapies for metastatic colorectal cancer. 60.00%
Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glyc 60.00%
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase path-- 60.00%
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". 60.00%
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? 60.00%
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary stu 60.00%
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel 60.00%
Clinical management of adrenocortical carcinoma 60.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp 60.00%
Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of 60.00%
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer 60.00%
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... 60.00%
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and m 60.00%
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi 60.00%
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. 70.00%
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo 70.00%
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. 70.00%
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses 70.00%
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. 70.00%
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. 70.00%
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-indep.. 70.00%
Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for NSCLC. 70.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. 70.00%
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. 70.00%
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. 70.00%
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer 70.00%
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. 70.00%
A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose-Escalation, Safety Study of the Chemot 70.00%
Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. 70.00%
Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemi 70.00%
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline 70.00%
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. 70.00%
Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. 70.00%
Sorafenib and radiation: A promising combination in colorectal and pancreas cancer 70.00%
Local ultrasound hyperthermia as a component of radiotherapy for osteogenic sarcoma of tubular bones in children and adolescents 70.00%
p53 as a specific prognostic factor in triple-negative breast cancer. 75.00%
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient 80.00%
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. 80.00%
Bevacizumab for recurrent ependymoma. 80.00%
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. 80.00%
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract 80.00%
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds 80.00%
Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGN 80.00%
Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled 80.00%
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma 80.00%
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytot..... 80.00%
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocy.. 80.00%
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. 80.00%
Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual sta 80.00%
Comparative evaluation of the complex treatment of rectal cancer patients (chemotherapy and X-ray therapy, Ukrain monotherapy) 80.00%
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt 80.00%
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.. 80.00%
Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. 80.00%
Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy. Results from 64 patients treated from 80.00%
Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside. 80.00%

Pages